Cytokinetics (CYTK) PT Raised to $48 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil rises as renewed US-Iran strikes stoke supply fears
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
Cytokinetics (CYTK) PT Raised to $69 at H.C. Wainwright
December 20, 2021 11:44 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $69.00 (from $62.00) while maintaining a Buy rating.
The analyst commented, "This morning, Cytokinetics and Ji Xing Pharmaceuticals Limited (private) announced an expansion of their existing partnership by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the treatment of HFrEF... More
Cytokinetics (CYTK) Expands Collaboration with JI XING to Include Licensing of Omecamtiv Mecarbil in China
December 20, 2021 7:32 AM ESTCytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited (JI XING), a biopharmaceutical company based in Shanghai and backed by RTW Investments, LP (RTW), today announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China. In addition to the license and collaboration agreement with JI XING, Cytokinetics has also entered into Common Stock Purchase Agreements that provide for the sale and issuance to entities affiliated with RTW... More
